Humacyte price target raised to $15 from $12 at H.C. Wainwright

H.C. Wainwright analyst Vernon Bernardino raised the firm’s price target on Humacyte (HUMA) to $15 from $12 and keeps a Buy rating on the shares after the FDA granted full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.